TWA
ICPT

TCI Wealth Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

TCI Wealth Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-243
Closed -$3.26K – 2449
2023
Q1 		$3.26K Hold
243
– – ﹤0.01% 1813
2022
Q4 		$3.01K Buy
+243
New +$3.44K ﹤0.01% 1858

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

TCI Wealth Advisors's ICPT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 243 shares — an estimated $3.26K sold.

TCI Wealth Advisors first reported a position in ICPT in Q4 2022 and held it in 2 quarters. The position peaked at $3.26K in Q1 2023. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 243 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3.26K.
  • TCI Wealth Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
  • TCI Wealth Advisors's Intercept Pharmaceuticals, Inc. position peaked at $3.26K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.